Navigation Links
Afraxis and PsychoGenics Form Alliance to Offer Afraxis' ESP Technology for Drug Discovery
Date:7/16/2012

SAN DIEGO and TARRYTOWN, New York, July 16, 2012 /PRNewswire/ -- Afraxis and PsychoGenics today announced an alliance to offer Afraxis' Enhanced Spine Platform (ESP) technology as part of PsychoGenics' comprehensive testing capabilities and drug discovery services. ESP rapidly assesses the quantity, morphology and maturity of dendritic spines, structures that mediate signaling in neural synapses, and can be used to evaluate disease models and in vivo preclinical efficacy and safety of therapeutics for central nervous system (CNS) and other disorders.

Abnormal dendritic spine quantity and morphology have been associated with numerous CNS disorders, including schizophrenia, Alzheimer's disease, Fragile X syndrome and autism. Evaluation of the effect of drug candidates on dendritic spine morphology can be a meaningful predictor of human efficacy, but conventional approaches to dendritic spine analysis are slow and cumbersome. The ESP technology is substantially faster than conventional methods and can evaluate as many as 250,000 dendritic spines per month. The approach used in ESP technology can simultaneously evaluate spine quantity and morphology in multiple brain regions.

"I believe that ESP offers a powerful approach to drug discovery in CNS diseases, and we are pleased to partner with Afraxis to offer this technology to our fee-for-service clients and partners," said Emer Leahy, Ph.D., President and CEO of PsychoGenics. "This expansion of PsychoGenics' service offerings enables our clients and partners to identify drug candidates with a higher likelihood of success in a time and cost efficient manner."

ESP technology is highly adaptable to many CNS disease models and can be used as a high-throughput complement to PsychoGenics' behavioral and physiological assays to assess disease models, preclinical drug efficacy and dosing regimens for future studies.

"ESP is a robust platform for drug discovery in CNS diseases that generates highly reproducible results through large data sets and redundant analysis using objective spine morphology classification criteria," said Jay Lichter, Ph.D., President and CEO of Afraxis. "Afraxis developed ESP to characterize potential drug candidates for our own discovery program in Fragile X syndrome, and now partnering with PsychoGenics allows us to offer the technology to other companies pursuing CNS drug discovery."

About PsychoGenics Inc.

PsychoGenics is a preclinical CRO that provides a full complement of partnered drug discovery capabilities with a focus on psychiatric, cognitive and neurodegenerative disorders, pain, inflammation, spinal cord and traumatic brain injury. PsychoGenics transforms drug discovery by combining expertise in behavioral neurobiology with the power of bioinformatics in conjunction with proprietary, high-throughput behavioral testing platforms that rapidly screen compound libraries for CNS activity. PsychoGenics works with pharmaceutical and biotechnology companies, academic institutions, and not-for-profit research foundations to help discover treatments for major neurological and psychiatric disorders.

For more information about PsychoGenics please visit www.psychogenics.com.

About Afraxis, Inc.

Afraxis, a San Diego-based biotechnology company fully funded by Avalon Ventures, is discovering and developing drugs to treat rare and neglected diseases through the modulation of p21-activated kinase (PAK). Afraxis' initial indication of interest is Fragile X syndrome with expansion into other diseases of the central nervous system, including schizophrenia and autism spectrum disorders. Recent scientific discoveries have linked these disorders to underlying defects in the development and function of specialized structures of the neural synapse, called dendritic spines. The company's lead target is PAK, a protein that regulates the development and activity of dendritic spines, creating potentially disease-modifying therapies rather than symptomatic treatments. Modifying the disease produces beneficial changes at the cellular and behavioral level, creating new hope for patients, their families and their caregivers.  In addition to its impact on dendritic spine biology, PAK is also implicated in cancer, including Neurofibromatosis, a rare form of cancer for which there are no approved drugs. Inhibiting PAK activity has the potential to induce significant anti-tumor activity.

For more information visit the Afraxis Web site: www.afraxis.com


'/>"/>
SOURCE Afraxis; PsychoGenics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Genomind to Participate in National Alliance on Mental Illness (NAMI) 2012 National Convention
2. Clean Energy Alliance and the Manufacturing Extension Partnership Announce New Collaboration
3. Economic Alliance of Greater Baltimore Inks Business Partnership with BioHealth Innovation to Bring Health and Life Sciences Research to Market
4. Alliance for Safe Biologic Medicines Chairman Urges FDA to Ensure that Patient Safety is the Cornerstone of Biosimilar Pathway
5. Donor Alliance Honors Families at the 2012 Donor Family Tribute
6. Genomic Health and OncoMed Announce Strategic Alliance for Biomarker Research and Discovery Using Next Generation Sequencing
7. Donor Alliance Honored By Colorado Legislature In Observation Of National Donate Life Month
8. Music Legend And Health Advocate Bret Michaels To Address Diversity Alliance For Science 2012 National Conference And EXPO
9. Narayana Hrudayalaya Hospitals Teams With Ascension Health Alliance to Build Health City at Grand Cayman
10. Psyche Systems Corporation Signs Strategic Alliance with Siemens Healthcare to Provide Anatomic Pathology Solutions
11. framergyTM to partner with the Space Alliance Technology Outreach Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 22, 2016  Amgen (NASDAQ: AMGN ... QB3@953 life sciences incubator to accelerate the ... shared laboratory space at QB3@953 was created to help ... obstacle for many early stage organizations - access to ... sponsorship, Amgen launched two "Amgen Golden Ticket" awards, providing ...
(Date:6/22/2016)... , June 22, 2016 Research and ... Global Markets" report to their offering. ... billion in 2014 from $29.3 billion in 2013. The market is ... of 13.8% from 2015 to 2020, increasing from $50.6 billion in ... projected product forecasts during the forecast period (2015 to 2020) are ...
(Date:6/22/2016)... ... June 22, 2016 , ... Quantitative Radiology Solutions, ... and current participant in the Phase 1 Ventures program, is leveraging regional and ... Quantitative Radiology Solutions helps physicians make better treatment decisions by quantifying medical imaging ...
(Date:6/22/2016)... ... 22, 2016 , ... The Immigrant Journey Awards , ... to North Texas and the nation, recently held its annual luncheon program. ... civic and economic vitality of North Texas. Proceeds from the event are used ...
Breaking Biology Technology:
(Date:5/16/2016)...   EyeLock LLC , a market leader of ... an IoT Center of Excellence in Austin, ... of embedded iris biometric applications. EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
Breaking Biology News(10 mins):